The reduced burn rate and extended cash runway into 2027 de-risk near-term financing needs, but declining collaboration revenue raises concerns about near-term income sustainability. Positive preclinical data and regulatory progress on MGX-001 provide upside potential ahead of IND filing in 2026 — monitor for clinical trial initiation updates in 2027.
Price Chart
Executive Summary
Metagenomi Therapeutics (MGX) reported its full-year 2025 financial results, highlighted by a significant reduction in R&D and G&A expenses, a strong cash position of $160.8 million, and key preclinical advances in its MGX-001 hemophilia A program, including curative FVIII activity in non-human primates. The company also completed a pre-IND meeting and rebranded to reflect its strategic focus on in vivo genome editing, with an IND submission expected in Q4 2026.
Key Financial Metrics
Key Facts
- Cash, cash equivalents, and marketable securities totaled $160.8 million as of December 31, 2025, with runway into Q4 2027.
- R&D expenses decreased to $94.4 million in 2025 from $109.2 million in 2024.
- G&A expenses declined to $26.8 million from $32.0 million year-over-year.
- Net loss was $87.9 million in 2025 vs. $78.1 million in 2024, despite lower operating expenses, due to reduced collaboration revenue.
- Collaboration revenue dropped to $25.2 million from $52.3 million in 2024.
- Preclinical data for MGX-001 in hemophilia A showed curative FVIII activity in NHPs; pre-IND meeting completed, IND planned for Q4 2026.
- Company rebranded to Metagenomi Therapeutics to reflect strategic evolution.
Financial Impact
Revenue down 51.8% YoY ($27.1M decline), operating expenses down 14.1% ($19.9M reduction), net loss widened by $9.8M due to lower collaboration income.
Risk Factors
- Heavy reliance on future clinical and regulatory milestones for value creation.
- Declining collaboration revenue may signal reduced partnership activity or near-term commercial uncertainty.
- Preclinical success does not guarantee clinical efficacy or safety.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250666 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $1.14 $0.8310 | ▼ −27.11% | ▼ −26.55% | $0.7610 (−33.25%) |
Aug 10, 2026 11w ago | 8-K | $1.21 $1.15 | ▲ +4.96% | ▲ +3.90% | $0.7610 (+37.11%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7610 (−38.13%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7610 (−38.13%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7610 (−38.13%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7610 (−38.13%) |
Jun 10, 2026 19w ago | Insider Cluster | $1.23 $1.26 | ▲ +2.44% | ▼ −1.18% | $0.7610 (−38.13%) |
May 11, 2026 24w ago | 8-K | $1.35 $1.23 | ▼ −8.89% | ▼ −7.16% | $0.7610 (−43.63%) |
May 11, 2026 24w ago | Press Release | $1.35 $1.23 | ▲ +8.89% | ▲ +7.16% | $0.7610 (+43.63%) |
Apr 27, 2026 26w ago | DEFA14A | $1.44 $1.36 | ▼ −5.56% | ▼ −11.02% | $0.7610 (−47.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers